PULMONX CORP

LUNGNASDAQ

🏆 #4169 by market capEarnings Nov 10 · PostUS Equity

$1.99▲ $0.02 (+1.02%)

Market closed · at close

🔔

Track LUNG

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 1.0%

7d▼ 0.7%

14d▲ 1.5%

30d▼ 16.9%

ytd▼ 10.2%

1y▲ 21.8%

🏦Market Cap

$84M

Small Cap

📈Revenue Growth (YoY)

-3.4%

Declining

📊Gross Margin

77.1%

High

💵FCF Margin

—

⚖️P/S Ratio

1.0x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $1.97 – $2.00
52-Week Range: $1.13 – $2.89
Volume: $2.69B
Avg Volume: $3.18B
Shares Outstanding: 42.2M
Next Earnings: Dec 9, 2026

Fundamentals Snapshot

Annual Revenue: $90M
Last Q Revenue: $23M
P/E Ratio: —
P/S Ratio: 1.0x
EPS (TTM): $-1.16
Dividend Yield: —
Dilution (1yr): +5.9%

Why Investors Own LUNG

✓High-growth profile — revenue up +36.3% YoY with expanding US Equity exposure.
✓Healthy economics — 47% gross margin and 15% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PULMONX CORP

LUNG

Financial Trends

Revenue

$90M▲ +8.0% YoY

Gross Margin

74.2%▲ +0.3% YoY

Operating Income

−$54M▼ −7.0% YoY

Free Cash Flow

−$33M▼ −0.3% YoY

Shares Outstanding

41.4M▲ +5.9% YoY

Net Cash

$14M▼ −$789K YoY

StockOtter · stockotter.space

About PULMONX CORP

Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.

🦦